Best Non-Controlled Medication for Severe Anxiety with Stimulant Use Disorder

Primary Recommendation: SSRIs as First-Line Treatment

The American Academy of Child and Adolescent Psychiatry recommends sertraline as the initial choice for patients with severe anxiety and stimulant use disorder due to its robust evidence base in anxiety disorders and lower propensity for drug interactions 1, 2
Sertraline has proven efficacy across multiple anxiety disorders, including generalized anxiety disorder, panic disorder, and social anxiety disorder, and is well-tolerated with manageable side effects in the dose range of 50-200 mg daily 1, 2
The American Academy of Child and Adolescent Psychiatry suggests that escitalopram or citalopram are excellent alternatives if sertraline is not tolerated, with the least effect on CYP450 isoenzymes compared to other SSRIs, resulting in lower propensity for drug interactions 1, 2

The American Academy of Child and Adolescent Psychiatry advises exercising caution when combining SSRIs with stimulants due to serotonin syndrome risk, and recommends starting at a low dose and increasing slowly, monitoring especially in the first 24-48 hours after dosage changes 1, 2
Stimulants can trigger serotonin syndrome when combined with SSRIs, and patients should be watched for symptoms such as mental status changes, neuromuscular hyperactivity, and autonomic hyperactivity 2

The American Academy of Child and Adolescent Psychiatry recommends starting with a subtherapeutic "test" dose of SSRIs, and increasing the dose as tolerated in smallest available increments at 1-2 week intervals for shorter half-life SSRIs like sertraline 1

The American Academy of Child and Adolescent Psychiatry suggests considering duloxetine if SSRIs are ineffective or not tolerated, as it is the only SNRI with FDA indication for generalized anxiety disorder in patients 7 years and older 3
Duloxetine has been associated with sustained hypertension and increased blood pressure, requiring monitoring, particularly given stimulant use can also elevate blood pressure 3

The American Academy of Child and Adolescent Psychiatry advises against using benzodiazepines, stimulants for anxiety, and MAO inhibitors in patients with severe anxiety and stimulant use disorder due to high abuse potential, contraindication in patients with active substance abuse history, and severe serotonin syndrome risk, respectively 2, 4, 5

The American Academy of Child and Adolescent Psychiatry recognizes that anxiety symptoms may be substance-induced, and recommends assessing anxiety after a period of abstinence when possible to distinguish primary anxiety disorder from substance-induced symptoms 5
No pharmacologic treatment exists for stimulant dependence itself, and behavioral therapies remain the mainstay for stimulant use disorder treatment, with SSRIs treating the co-occurring anxiety disorder, not the stimulant dependence 6

The American Academy of Child and Adolescent Psychiatry recommends regular monitoring for suicidal thinking and behavior, behavioral activation, agitation, or hypomania, discontinuation syndrome, and using standardized symptom rating scales to track treatment response 1, 2

Anxiety disorders often require higher SSRI doses than depression, with higher doses associating with greater efficacy but also higher dropout rates due to adverse effects, according to the Nature Reviews Disease Primers 7
Treating underlying conditions often improves comorbid anxiety, as shown by modern evidence from the Journal of the American Academy of Child and Adolescent Psychiatry 8

The American Academy of Child and Adolescent Psychiatry suggests that higher SSRI doses are typically needed for anxiety, but starting with low doses is recommended in stimulant use disorder due to interaction risks 7